Ranbaxy Laboratories
-
{
- All
- News
- Videos
-
Cipla, Maruti Suzuki, JSW Steel in Focus Today
The Nifty opened lower on Tuesday tracking futures trade on Singapore Stock Exchange. Foreign investors were net sellers of Indian equities to the tune of Rs 63 crore on Wednesday. However domestic investors had bought shares worth Rs 156 crore in cash market. Sentiment is likely to be positive today on the back of lower crude oil prices.
-
Wipro, Ambuja Cements, JP Power in Focus Today
The Nifty opened flat on Friday as indicated by futures trade on Singapore Stock Exchange. Foreign investors remained net buyers in Indian equities to the tune of Rs 282 crore whereas domestic investors sold shares worth Rs 290 crore on Thursday. Nifty closed positive for the eighth straight session on Thursday with record highs.
-
Bharti Airtel, L&T, Dr Reddy's Lab in Focus Today
The Nifty opened lower on Wednesday as indicated by futures trade on Singapore Stock Exchange. Both foreign and domestic investors remain net buyers of Indian shares on Monday. Foreign investors bought shares worth Rs 75 crore and domestic investors bought shares worth Rs56 crore. Stock specific action driven by earning is likely to be seen in mark...
-
Ranbaxy, United Spirits, SpiceJet in Focus Today
The Nifty opened higher on Friday tracking higher global markets. Nifty futures traded on Singapore Stock Exchange also indicate towards an opening above 7,900. Foreign investors continue to be net buyers of Indian equities for the seventh straight session. FIIs bought cash shares worth Rs 413 crore on Thursday and domestic investors were net buyer...
-
Jet Airways, Adani Power, IRB Infra in Focus Today
The Nifty opened higher on Monday. Foreign investor continued to remain net buyers of Indian equities for the eighth straight session. FIIs bought shares worth Rs 302 crore on Friday whereas domestic investors sold shares worth Rs 184 crore in the cash market. Brent crude price which is below $102 per barrel is likely to trigger further buying in o...
-
Corporate Earnings, Overseas Investors to Remain in Focus This Week: Experts
With no major data due this week, investors in Indian stock markets are expected to focus on the ongoing quarterly earnings and foreign fund inflows for further cues, according to analysts.
-
Sun Pharma Q4 Net Profit Rises 57 Per Cent to Rs 1,587 Crore
Sun Pharmaceutical Industries Ltd, India's third-largest drugmaker by revenue, on Thursday reported a 57 per cent jump in fourth-quarter net profit, slightly above expectations, helped by higher sales in the United States, its largest market.
-
CCI Says Sun's Takeover of Ranbaxy May Hurt Competition
The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition", according to a government statement on Thursday and a document posted on the regulator's website.
-
Pfizer, Ranbaxy Win Dismissal of Lawsuit Over Generic Lipitor
US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail.
-
Ranbaxy Says US Authorities Seek Information on Pricing Data
Generics drug maker Ranbaxy Laboratories Ltd on Wednesday said federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.
-
Sun Pharma, Ranbaxy Surge Over 5%
Sun Pharmaceutical Industries stock gained more than 6 per cent on Friday, heading towards its biggest single-day gain since April 9.
-
Ranbaxy Launches Acne Treatment Capsules in US
Drug firm Ranbaxy Laboratories on Wednesday launched a capsule used for treatment of severe acne in the US.
-
Ranbaxy Launches Acne Treatment Capsules in US
Drug firm Ranbaxy Laboratories on Wednesday launched a capsule used for treatment of severe acne in the US.
-
Ranbaxy to Pay $40 Million to Settle Texas Litigation
Ranbaxy's Texas settlement comes after the company pleaded guilty last year to felony charges relating to drug safety. It agreed to pay $500 million in civil and criminal fines under a settlement agreed with the Department of Justice.
-
No CCI Directive to Sell Business For Merger Nod with Sun Pharma: Ranbaxy
The company also said it and Sun Pharma were awaiting Competition Commission of India (CCI) decision on "certain submissions" over their merger deal.
-
Cipla, Maruti Suzuki, JSW Steel in Focus Today
The Nifty opened lower on Tuesday tracking futures trade on Singapore Stock Exchange. Foreign investors were net sellers of Indian equities to the tune of Rs 63 crore on Wednesday. However domestic investors had bought shares worth Rs 156 crore in cash market. Sentiment is likely to be positive today on the back of lower crude oil prices.
-
Wipro, Ambuja Cements, JP Power in Focus Today
The Nifty opened flat on Friday as indicated by futures trade on Singapore Stock Exchange. Foreign investors remained net buyers in Indian equities to the tune of Rs 282 crore whereas domestic investors sold shares worth Rs 290 crore on Thursday. Nifty closed positive for the eighth straight session on Thursday with record highs.
-
Bharti Airtel, L&T, Dr Reddy's Lab in Focus Today
The Nifty opened lower on Wednesday as indicated by futures trade on Singapore Stock Exchange. Both foreign and domestic investors remain net buyers of Indian shares on Monday. Foreign investors bought shares worth Rs 75 crore and domestic investors bought shares worth Rs56 crore. Stock specific action driven by earning is likely to be seen in mark...
-
Ranbaxy, United Spirits, SpiceJet in Focus Today
The Nifty opened higher on Friday tracking higher global markets. Nifty futures traded on Singapore Stock Exchange also indicate towards an opening above 7,900. Foreign investors continue to be net buyers of Indian equities for the seventh straight session. FIIs bought cash shares worth Rs 413 crore on Thursday and domestic investors were net buyer...
-
Jet Airways, Adani Power, IRB Infra in Focus Today
The Nifty opened higher on Monday. Foreign investor continued to remain net buyers of Indian equities for the eighth straight session. FIIs bought shares worth Rs 302 crore on Friday whereas domestic investors sold shares worth Rs 184 crore in the cash market. Brent crude price which is below $102 per barrel is likely to trigger further buying in o...
-
Corporate Earnings, Overseas Investors to Remain in Focus This Week: Experts
With no major data due this week, investors in Indian stock markets are expected to focus on the ongoing quarterly earnings and foreign fund inflows for further cues, according to analysts.
-
Sun Pharma Q4 Net Profit Rises 57 Per Cent to Rs 1,587 Crore
Sun Pharmaceutical Industries Ltd, India's third-largest drugmaker by revenue, on Thursday reported a 57 per cent jump in fourth-quarter net profit, slightly above expectations, helped by higher sales in the United States, its largest market.
-
CCI Says Sun's Takeover of Ranbaxy May Hurt Competition
The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition", according to a government statement on Thursday and a document posted on the regulator's website.
-
Pfizer, Ranbaxy Win Dismissal of Lawsuit Over Generic Lipitor
US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail.
-
Ranbaxy Says US Authorities Seek Information on Pricing Data
Generics drug maker Ranbaxy Laboratories Ltd on Wednesday said federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.
-
Sun Pharma, Ranbaxy Surge Over 5%
Sun Pharmaceutical Industries stock gained more than 6 per cent on Friday, heading towards its biggest single-day gain since April 9.
-
Ranbaxy Launches Acne Treatment Capsules in US
Drug firm Ranbaxy Laboratories on Wednesday launched a capsule used for treatment of severe acne in the US.
-
Ranbaxy Launches Acne Treatment Capsules in US
Drug firm Ranbaxy Laboratories on Wednesday launched a capsule used for treatment of severe acne in the US.
-
Ranbaxy to Pay $40 Million to Settle Texas Litigation
Ranbaxy's Texas settlement comes after the company pleaded guilty last year to felony charges relating to drug safety. It agreed to pay $500 million in civil and criminal fines under a settlement agreed with the Department of Justice.
-
No CCI Directive to Sell Business For Merger Nod with Sun Pharma: Ranbaxy
The company also said it and Sun Pharma were awaiting Competition Commission of India (CCI) decision on "certain submissions" over their merger deal.
